Durable audit route for one claim-like target. This page shows source-use records, assessment rationale, active challenges, revisions, and graph edges tied to the same target identity.
neuroplasticity support is included with provisional confidence because the record has direct section evidence but still needs endpoint-specific interpretation before it should be read as a strong clinical claim.
The assessment is anchored to the cited effect record rather than inferred from the compound name alone.
Sources considered for this assessment[1]
The row has an explicit structured record and citation mapping.
The current seed evidence does not yet carry the same detailed endpoint interpretation as Taurine.
The audit path is present; additional source interpretation can be added without changing the schema.
Associated with synaptic density and plasticity markers in preclinical and translational models.
This source is used to support the Neuroplasticity Support effect row in this compound monograph.